In Q4 2025, Amgen Inc. reported solid financial results with a revenue growth of 12.4% year-over-year (YoY) and an operating margin of 24.11%, which is above the sector average of 14.5%. The company's net margin stood at 19.47%, also higher than the industry benchmark. Despite a slight decline in quarterly profit growth of -4.89% QoQ, Amgen's full-year earnings for 2025 were impressive, with a 10% revenue increase.
Looking at the growth trends, Amgen's 3-year revenue CAGR and 3-year profit CAGR remain unknown. However, the company has managed to achieve consecutive growth quarters in Q4 2025, which is a positive sign for investors. Additionally, Wall Street analysts have raised price targets for Amgen based on its strong earnings performance and solid financial position.
Amgen's latest quarterly results are reflected in its current stock price, which trades near 52-week highs. Positive catalysts such as the company's robust Q4 and full-year 2025 earnings, along with a recent increase in price targets, suggest a bullish outlook for Amgen's near-term prospects.
Despite these strengths, potential concerns for Amgen include competitive pressures within the healthcare sector and regulatory risks that could impact its business operations. Nevertheless, the company's solid financial performance and positive news sentiment make it an attractive investment opportunity for those seeking exposure to the healthcare sector.
Moving forward, investors should closely monitor Amgen's growth trajectory, profitability, and any potential risks or challenges that may arise. With its strong earnings and raised price targets, Amgen continues to position itself as a leader in the healthcare industry, making it a compelling investment option for those looking for long-term growth potential.